-

QIAGEN N.V. to release results for Q1 2022 and hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time / 21:05 London time / 16:05 New York time

Call date/time: Thursday, April 28, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time.

Hosts: Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

Three options for joining the call

 

 

 

 

Register for call back
connection

 

Click here:

Connect Me

 

 

Service available 15
minutes before call start

Dial-in by phone

 

 

+1 929 477 0402 (U.S.)

+44 (0)330 165 3655 (UK)

+49 (0)69 2222 25574 (GER)

 

To avoid waiting time, please
join the event conference 5-
10 minutes prior to the start
time.

 

Conference ID: 6602996

 

Access the audio
webcast

 

Click here:

Access webcast

 

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1538117&tp_key=754eca7ed7

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies), and Academia (life sciences research). As of December 31, 2021, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

Industry:

QIAGEN N.V.

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
Release Versions
English

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,...

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...

QIAGEN Appoints Mark Stevenson to Supervisory Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Ket...
Back to Newsroom